INONasdaqPharmaceutical PreparationsFiscal year ends December 31

INOVIO PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$1.00+0.01 (+1.00%)

Close on Oct 19, 2026

Market cap: $81.62M
P/E (TTM): –
Dividend yield: –

INOVIO PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	0.07	0.22	0.83	10	1.77	7.41	4.11	30	42	35	41	10	13	4.12	9.80	6.14	9.12
Research & Development	54	76	87	188	249	94	88	95	99	89	58	34	21	18	20	13	9.41
General & Administrative	33	37	48	90	54	37	27	29	28	24	18	16	14	11	12	12	14
Operating Expenses	87	113	145	278	303	131	115	125	126	112	75	50	33	28	31	25	23
Operating Income	-87	-112	-144	-268	-301	-124	-111	-94	-84	-76	-34	-39	-20	-23	-22	-19	-14
Interest Expense	0	0.18	1.22	1.25	1.94	8.70	7.95	0	0.03	–	–	–	–	–	–	–	–
Interest & Investment Income	2.42	4.77	8.13	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Equity Investments	–	–	0	-2.17	-0.43	-4.58	0	0	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-2.64	-3.16	-4.71	-3.86	0.34	-0.70	0.50	-1.34	-0.20	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	0	11	0	0	0	0	–	–	–	0	0	0	0	0	0	–
Gain (Loss) on Investments	–	–	–	–	–	-0.59	0.48	-1.34	-0.22	–	–	–	–	–	–	–	1.14
Gain (Loss) on Sale of Assets	0	0.02	-0.32	-1.07	0	-0.03	-0.01	-0.01	0	0	-0.01	0.00	0.00	0	0	-0.02	-0.03
Pretax Income	-85	-107	-135	-278	-303	-163	-121	-95	-88	-74	-31	-36	-66	–	–	–	–
Income Tax Expense	0	0	0	0	0	0	-0.26	2.17	0	0	-2.10	0	0	0.03	0.03	0.07	–
Net Income incl. Noncontrolling Interests	–	–	–	-280	-304	-167	-121	-97	-88	-74	-29	-36	-66	-20	-15	-18	-24
Minority Interest in Earnings	–	–	–	0	0	-1.06	-1.19	0	0	0	0.08	-0.02	-0.06	-0.04	-0.05	-0.02	-0.05
Net Income	-85	-107	-135	-280	-304	-166	-119	-97	-88	-74	-29	-36	-66	-20	-15	-18	-24
Net Income to Common	–	–	–	–	–	–	-119	-97	-89	-74	-30	-38	-66	-20	–	–	–
EPS (Basic)(per share)	-1.81	-3.95	-6.09	-14.07	-17.45	-12.84	-14.52	-12.60	-12.96	-12.12	-5.16	-7.32	-17.16	-6.96	-5.76	-8.16	-15.84
EPS (Diluted)(per share)	-1.81	-3.95	-6.09	-14.07	-17.45	-12.84	-14.52	-12.60	-13.08	-12.12	-5.28	-7.68	-17.16	-6.96	-5.76	-8.16	-15.84
Shares Outstanding (Basic, Weighted)(shares)	47	27	22	20	17	13	8.23	7.71	6.81	6.10	5.68	4.93	3.84	2.84	2.63	2.15	–
Shares Outstanding (Diluted, Weighted)(shares)	47	27	22	20	17	13	8.23	7.71	6.83	6.10	5.70	4.95	3.84	2.84	2.63	2.15	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -183.5%

Financial strength

Current ratio: 1.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 79.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 18.67
Dividend yield: –